Jeff Yass’s Aclaris Therapeutics ACRS Stock Holding History

Jeff Yass’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$281K	Sell	53,100 -81,800	-61%	-$365K	﹤0.01%	11198
2026 Q1	$506K	Buy	+134,900	New	+$455K	﹤0.01%	9636
2025 Q1	–	Sell	-91,300	Closed	-$226K	–	12372
2024 Q4	$226K	Buy	+91,300	New	+$227K	﹤0.01%	10451
2024 Q2	–	Sell	-15,700	Closed	-$19.5K	–	11922
2024 Q1	$19.5K	Sell	15,700 -6,400	-29%	-$7.63K	﹤0.01%	11824
2023 Q4	$23.2K	Sell	22,100 -51,900	-70%	-$158K	﹤0.01%	11946
2023 Q3	$507K	Sell	74,000 -34,300	-32%	-$293K	﹤0.01%	8189
2023 Q2	$1.12M	Sell	108,300 -61,700	-36%	-$558K	﹤0.01%	6410
2023 Q1	$1.38M	Buy	170,000 +150,300	+763%	+$1.91M	﹤0.01%	6015
2022 Q4	$310K	Buy	19,700 +900	+5%	+$14.5K	﹤0.01%	9021
2022 Q3	$296K	Buy	18,800 +4,900	+35%	+$77.2K	﹤0.01%	9824
2022 Q2	$194K	Buy	13,900 +3,000	+28%	+$42K	﹤0.01%	10679
2022 Q1	$188K	Buy	+10,900	New	+$149K	﹤0.01%	11303
2021 Q3	–	Sell	-75,000	Closed	-$1.32M	–	12652
2021 Q2	$1.32M	Sell	75,000 -25,800	-26%	-$586K	﹤0.01%	6999
2021 Q1	$2.54M	Buy	100,800 +89,800	+816%	+$1.76M	﹤0.01%	5342
2020 Q4	$71K	Buy	+11,000	New	+$46.4K	﹤0.01%	10638
2019 Q4	–	Sell	-10,300	Closed	-$11K	–	9615
2019 Q3	$11K	Sell	10,300 -36,200	-78%	-$51.4K	﹤0.01%	10009
2019 Q2	$102K	Buy	46,500 +1,000	+2%	+$5.45K	﹤0.01%	9593
2019 Q1	$273K	Buy	+45,500	New	+$302K	﹤0.01%	7378
2018 Q3	–	Sell	-18,000	Closed	-$359K	–	9097
2018 Q2	$359K	Buy	18,000 +3,500	+24%	+$64.7K	﹤0.01%	7480
2018 Q1	$254K	Sell	14,500 -45,900	-76%	-$973K	﹤0.01%	7907
2017 Q4	$1.49M	Buy	60,400 +46,700	+341%	+$1.14M	﹤0.01%	4469
2017 Q3	$354K	Buy	+13,700	New	+$367K	﹤0.01%	7108

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Jeff Yass's ACRS Position: Q2 2026 in Review

Jeff Yass increased its Aclaris Therapeutics (ACRS) stake by 8.6% in Q2 2026, buying an estimated $145K and bringing the position to 412,549 shares worth $2.18M. The position accounts for ﹤0.01% of the portfolio, ranked #6289.

Jeff Yass first reported a position in ACRS in Q1 2017 and has held it in 29 quarters since. The position peaked at $11.3M in Q1 2021. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

Jeff Yass held 412,549 shares of Aclaris Therapeutics worth $2.18M as of Q2 2026.
Jeff Yass bought 32,619 Aclaris Therapeutics shares in Q2 2026, an estimated $145K.
Aclaris Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #6289 holding.
Jeff Yass first reported a position in Aclaris Therapeutics in Q1 2017 and has held it in 29 quarters since.
Jeff Yass's Aclaris Therapeutics position peaked at $11.3M in Q1 2021.
148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.